NCT05654870

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Neurocrine Biosciences · Industry
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Valbenazine	Oral treatment
DRUG	Placebo	Placebo matching valbenazine

Timeline

• Start date: 2023-01-05
• Primary completion: 2023-11-08
• Completion: 2023-11-08
• First posted: 2022-12-16
• Last updated: 2024-11-12

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study